Skip to main content
Midas Edge

Turn Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

TTRX$9.92+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

Common Stock · Additional Paid-in · Subscription · Accumulated · Total Stockholders’
Shares · Amount · Capital · Receivable · Deficit · Equity
As at December 31, 202529,445,183$2,944$28,143,872$(1,070,000)$(22,390,093)$4,686,723
Issuance of common stock under Avenue Capital Loan Agreement342,857341,050,933--1,050,967
Cash receipt from stock subscription receivable---1,070,000-1,070,000
Stock-based compensation expense--280,830--280,830
Net loss----(970,972)(970,972)
As at March 31, 202629,788,040$2,978$29,475,635$-$(23,361,065)$6,117,548
Stock-based compensation expense--419,233--419,233
Net loss----(5,849,893)(5,849,893)
As at June 30, 202629,788,040$2,978$29,894,868$-$(29,210,958)$686,888
Issuance of common stock under Regulation D, net of issuance costs165,000171,640,993--1,641,010
Issuance of common stock upon exercise of warrant579,664588,881,884--8,881,942
Stock-based compensation expense--713,205--713,205
Net loss----(6,230,868)(6,230,868)
As at September 30, 202630,532,704$3,053$41,130,950$-$(35,441,826)$5,692,177
Common Stock · Additional Paid-in · Subscription · Accumulated · Total Stockholders’ Equity
Shares* · Amount* · Capital · Receivable · Deficit · (Deficit)
As at December 31, 202426,845,690$2,685$19,015,896$-$(19,196,013)$(177,432)
Issuance of common stock under Regulation Crowdfunding, net of issuance costs215,97222777,770--777,792
Issuance of common stock under Regulation D, net of issuance costs139,43614220,286--220,300
Issuance of common stock in exchange for advisory services54,4665249,995--250,000
Stock-based compensation expense--76,597--76,597
Net loss----(328,547)(328,547)
As at March 31, 202527,255,564$2,726$20,340,544$-$(19,524,560)$818,710
Issuance of common stock under Regulation A+, net of issuance costs83,6108280,484(247,234)-33,258
Issuance of common stock under Regulation D, net of issuance costs636,032642,515,549(400,082)-2,115,531
Issuance of common stock upon exercise of warrants47,6204234--238
Stock-based compensation expense--47,184--47,184
Net loss----(1,240,425)(1,240,425)
As at June 30, 202528,022,826$2,802$23,183,995$(647,316)$(20,764,985)$1,774,496
Cash receipt from stock subscription receivable---594,617-594,617
Stock-based compensation expense--39,084--39,084
Net loss----(1,904,184)(1,904,184)
As at September 30, 202528,022,826$2,802$23,223,079$(52,699)$(22,669,169)$504,013
*Retroactively adjusted for 2-for-1 forward stock split.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.